Fulcrum Therapeutics, Inc. last reported quarterly results on Apr 27, 2026, for Q1 FY2026 (the quarter ended Mar 31, 2026): diluted EPS of -$0.25. It usually reports 12–29 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–29 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Apr 27, 2026
27 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
-19
-7.0%
|
-0.25
+10.7%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
0
|
-20
-22.7%
|
0.11
+25.5%
|
|
Oct 29, 2025
29 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
0
|
-20
+9.7%
|
-0.31
+11.4%
|
|
Jul 29, 2025
29 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
0
-100.0%
|
-17
-131.2%
|
-0.28
-132.2%
|
|
May 1, 2025
31 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
—
|
-18
+34.3%
|
-0.28
+34.9%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
0
-100.0%
|
-17
+33.1%
|
0.09
-36.0%
|
|
Nov 13, 2024
44 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
0
-100.0%
|
-22
+9.7%
|
-0.35
+10.3%
|
|
Jul 31, 2024
31 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- FULC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1680581
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.